AC Immune SA
ACIU
Get informed when a big investor buys or sells
+ FollowMarket Cap$235.1M
Close$
$-0.10
104.2% downside
Current Fair Value
104.2% downsideOvervalued by 104.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $235.10 Million |
|---|---|
| Enterprise Value | $303.87 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.7 |
| Beta | 1.56 |
| Outstanding Shares | 98,673,333 |
Return
| Return on Equity | -209.65% |
|---|---|
| Return on Assets | -48.11% |
| Return on Invested Capital | -145.98% |
Valuation & Multiples
| P/E Ratio | -2.74 |
|---|---|
| PEG | 12.34 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 85.8 |
| Enterprise Value to EBIT | -4.61 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 2.79 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 30, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
$329,435
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$42.55 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1000▼ 15.77% |
|---|---|
| Total Calls | 357,000▲ 180.44% |
| Total Puts | 35,700▲ 8.84% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 24.79%▼ 1.22% |
|---|---|
| Total Invested | $68.97M▼ 14.77% |
| Investors Holding | 51▲ 4.00% |
ESG Score
No data
About AC Immune SA
CEO: Andrea Pfeifer